Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

IMMP

Immutep Limited ADR

Mar 13 • 04:00PM ET

0.4846

-2.1554 -81.64 %

Healthcare • Biotechnology • Australia • NASD

Today, 9:50 AMBaird downgrades Immutep to Neutral, cuts price target to $1 from $7 after TACTI-004 lung cancer study discontinued for futility

Peers: VRTX GILD REGN BMRN SRPT BIIB INCY ALNY IONS NBIX

| Held by: IBB

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.37	Insider Own	0.84%	Shs Outstand	147.37M	Perf Week	-81.64%
Market Cap	71.42M	Forward P/E	-	EPS next Y	-0.25	Insider Trans	0.00%	Shs Float	146.13M	Perf Month	-82.63%
Enterprise Value	6.13M	PEG	-	EPS next Q	-0.03	Inst Own	2.01%	Short Float	3.30%	Perf Quarter	-80.62%
Income	-54.17M	P/S	26.75	EPS this Y	5.19%	Inst Trans	4.00%	Short Ratio	6.48	Perf Half Y	-70.81%
Sales	2.67M	P/B	1.08	EPS next Y	5.43%	ROA	-51.34%	Short Interest	4.82M	Perf YTD	-83.06%
Book/sh	0.45	P/C	1.08	EPS next 5Y	-7.49%	ROE	-62.72%	52W High	3.53 -86.27%	Perf Year	-72.31%
Cash/sh	0.45	P/FCF	-	EPS past 3/5Y	-0.60% -4.46%	ROIC	-81.36%	52W Low	1.32 -63.29%	Perf 3Y	-70.81%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	46.21%	Volatility	8.18% 5.58%	Perf 5Y	-82.05%
Dividend TTM	-	EV/Sales	2.29	EPS Y/Y TTM	-69.60%	Oper. Margin	-2136.42%	ATR (14)	0.29	Perf 10Y	-85.46%
Dividend Ex-Date	-	Quick Ratio	2.97	Sales Y/Y TTM	-	Profit Margin	-2026.12%	RSI (14)	13.37	Recom	2.43
Dividend Gr. 3/5Y	- -	Current Ratio	2.97	EPS Q/Q	-96.37%	SMA20	-81.66%	Beta	1.74	Target Price	5.54
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	-82.85%	Rel Volume	61.82	Prev Close	2.64
Employees	-	LT Debt/Eq	0.01	Earnings	Feb 24 AMC	SMA200	-76.79%	Avg Volume	744.39K	Price	0.48
IPO	Apr 17, 2012	Option/Short	Yes / No	EPS/Sales Surpr.	-9.88% -41.49%	Trades		Volume	46,015,078	Change	-81.64%

Date	Action	Analyst	Rating Change	Price Target Change
Today	Downgrade	Robert W. Baird	Outperform → Neutral	$1
Today	Downgrade	Maxim Group	Buy → Hold
Today	Downgrade	Citizens	Mkt Outperform → Mkt Perform
Feb-17-26	Initiated	Citizens	Mkt Outperform	$6
May-17-24	Initiated	CapitalOne	Overweight	$10
Aug-03-23	Initiated	Robert W. Baird	Outperform	$7
Aug-03-21	Initiated	Ladenburg Thalmann	Buy	$8.30
Jul-16-21	Resumed	Maxim Group	Buy	$8
Sep-28-18	Initiated	B. Riley FBR	Buy	$7.75
Feb-15-18	Reiterated	Maxim Group	Buy	$7 → $5

Today 03:02PM	Immuteps LAG-3 hopes take a hit on Phase III NSCLC termination (Clinical Trials Arena) -81.64%
09:39AM	Adobe downgraded, Nio upgraded: Wall Street's top analyst calls (The Fly)
08:00AM	TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis (GlobeNewswire)
06:17AM	Evotec, Vistagen lay off staff; Immutep shares collapse on study failure (BioPharma Dive)
Feb-06-26 08:00AM	Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC (GlobeNewswire)
08:00AM	Loading…
Jan-29-26 08:00AM	Immutep Quarterly Activities Report Q2 FY26 (GlobeNewswire)
Jan-21-26 12:14PM	Dr. Reddy's Laboratories Q3 Earnings Call Highlights (MarketBeat)
Dec-22-25 08:00AM	Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study (GlobeNewswire)
Dec-16-25 08:00AM	Immutep Announces Strong Operational Progress in Global TACTI-004 (KEYNOTE-F91) Phase III and Enrolment Continues at Robust Pace (GlobeNewswire)
Dec-15-25 12:35PM	Immutep (IMMP) Scores Win After Announcing Deal With Indian Firm (Insider Monkey) -5.43%
Dec-10-25 02:13PM	Immutep Limited (IMMP): Firm Reports Positive Data from Trials (Insider Monkey) +11.11%
Dec-08-25 08:00AM	Immutep and Dr. Reddy's enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa (GlobeNewswire) +26.11%
Dec-02-25 08:00AM	Immutep to Present New Data from AIPAC-003 Phase II at the 2025 San Antonio Breast Cancer Symposium (GlobeNewswire) -7.07%
Nov-13-25 08:00AM	Translational Data and Significant Pathologic Response Rates from EFTISARC-NEO Phase II Highlighted in Oral Presentation at CTOS 2025 (GlobeNewswire)
Nov-03-25 08:00AM	Immutep Receives A$4.6 million R&D Tax Incentive from French Government (GlobeNewswire)
08:00AM	Loading…
Oct-29-25 08:00AM	Immutep Quarterly Activities Report Q1 FY26 (GlobeNewswire)
Oct-20-25 08:01AM	Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025 (GlobeNewswire)
08:00AM	Two Posters at ESMO Congress 2025 Highlight Immutep's Focus on Changing Treatment Landscape in First Line Non-Small Cell Lung Cancer (GlobeNewswire)
Oct-13-25 08:00AM	Immutep Announces Successful Completion of FDA Project Optimus Requirements (GlobeNewswire)
Oct-09-25 08:00AM	Immutep Announces Update for TACTI-004 (KEYNOTE-F91) Phase III Trial in First Line Non-Small Cell Lung Cancer (GlobeNewswire)
Sep-22-25 08:00AM	Immutep Announces Research Collaboration with the George Washington University Cancer Center to Evaluate Neoadjuvant Efti (GlobeNewswire) +6.21%
Sep-08-25 08:00AM	Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025 (GlobeNewswire)
Aug-17-25 01:52AM	Immutep Limited (IMMP) Receives Positive FDA Feedback on Future Clinical Development of Eftilagimod Alfa (Insider Monkey)
Jul-30-25 08:00AM	Immutep Quarterly Activities Report Q4 FY25 (GlobeNewswire)
Jul-29-25 08:00AM	Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer (GlobeNewswire)
Jul-28-25 08:00AM	Immutep Announces Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025 (GlobeNewswire)
Jun-29-25 01:28PM	Immutep (IMMP) Announces Positive Initial Efficacy Data and Continued Favourable Safety Data (Insider Monkey)
Jun-23-25 08:00AM	Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases (GlobeNewswire) -5.00%
May-27-25 08:00AM	Immutep's Efti with Radiotherapy & KEYTRUDA (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma (GlobeNewswire)
May-15-25 08:00AM	Immutep's Efti with KEYTRUDA (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer (GlobeNewswire) +8.20%
08:00AM	Loading…
Apr-29-25 08:00AM	Immutep Quarterly Activities Report Q3 FY25 (GlobeNewswire)
Apr-02-25 08:00AM	Immutep to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.65%
Mar-31-25 11:50AM	Immutep: A Small Company With A Pipeline Resembling Big Pharma (Seeking Alpha) -5.38%
Mar-25-25 08:00AM	First Patient Dosed in Immutep's TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer (GlobeNewswire)
Mar-20-25 08:00AM	Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the European Lung Cancer Congress 2025 (GlobeNewswire)
Jan-31-25 08:00AM	Immutep Quarterly Activities Report Q2 FY25 (GlobeNewswire)
Jan-22-25 08:00AM	Patient Enrolment Completed for EFTISARC-NEO Phase II Trial (GlobeNewswire)
Jan-06-25 08:00AM	Patient Enrolment Completed for INSIGHT-003 (GlobeNewswire)
Dec-17-24 08:00AM	Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761 (GlobeNewswire)
Dec-16-24 08:00AM	Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II (GlobeNewswire)
Dec-13-24 08:20AM	Immutep announces results from Cohort B of TACTI-003 trial (TipRanks)
Dec-12-24 08:15AM	Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024 (GlobeNewswire) -5.30%
Dec-10-24 08:00AM	Immutep Announces Initiation of TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer (GlobeNewswire)
Nov-14-24 08:15AM	Immutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer (GlobeNewswire) +11.76%
08:00AM	Positive Data from Phase II Trial in Soft Tissue Sarcoma Presented at CTOS 2024 Annual Meeting (GlobeNewswire)
Oct-29-24 08:00AM	Immutep Quarterly Activities Report Q1 FY25 (GlobeNewswire)
Oct-28-24 08:00AM	Immutep to Present New Phase IIb Data in PD-L1 Negative (CPS (GlobeNewswire)
Oct-17-24 08:00AM	Immutep Announces First-in-Human Phase I Study of IMP761 Progresses to Dose Escalation Portion of Trial (GlobeNewswire)
Oct-10-24 08:00AM	Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit (GlobeNewswire)
Oct-04-24 06:12AM	Immutep concludes participant enrolment in Phase II breast cancer trial (Clinical Trials Arena)
Oct-03-24 08:00AM	Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer (GlobeNewswire)
Sep-24-24 08:00AM	Immutep Receives A$3.6 million R&D Tax Incentive from French Government (GlobeNewswire)
Sep-18-24 08:00AM	New Data to be Presented from EFTISARC-NEO Phase II Evaluating Novel Triple Combination including Immutep's Efti in Soft Tissue Sarcoma (GlobeNewswire)
Sep-16-24 08:00AM	Immutep's Efti in Combination with MSD's KEYTRUDA Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer (GlobeNewswire) -12.50%
Aug-20-24 08:00AM	Immutep Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress 2024 (GlobeNewswire)
Aug-14-24 08:00AM	Immutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 Antibody (GlobeNewswire) +8.54%
Aug-07-24 08:00AM	Immutep to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jul-31-24 08:00AM	Immutep Quarterly Activities Report Q4 FY24 (GlobeNewswire)
Jul-22-24 08:00AM	Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer (GlobeNewswire)
Jul-17-24 08:00AM	Immutep Receives Regulatory Clearance for Phase I Study of First-in-Class LAG-3 Agonist Antibody Designed to Treat Autoimmune Diseases (GlobeNewswire)
Jul-15-24 08:39AM	Immutep (IMMP) Up as Combo Therapy Meets Carcinoma Study Goals (Zacks) -11.69%
Jul-12-24 09:15AM	Immutep tries to regain pep as cancer subgroup data show path forward with a long list of caveats (FierceBiotech.com) +14.93%
07:41AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
Jul-11-24 06:40PM	Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression (GlobeNewswire)
Jul-03-24 08:00AM	Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results (GlobeNewswire) +5.32%
Jun-27-24 07:34AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace) -32.49%
Jun-25-24 08:00AM	Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer (GlobeNewswire)
Jun-05-24 06:00AM	Immutep successfully completes institutional placement and institutional component of entitlement offer (GlobeNewswire) -12.08%
Jun-02-24 08:38PM	Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA (pembrolizumab) in Pivotal Phase III Trial (GlobeNewswire)
May-15-24 08:00AM	Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024 (GlobeNewswire)
May-02-24 08:00AM	Positive Initial Clinical Data Reported from Immutep's Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma (GlobeNewswire)
Apr-29-24 08:00AM	Immutep Quarterly Activities Report Q3 FY24 (GlobeNewswire)
Apr-24-24 08:00AM	Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B (GlobeNewswire)
Apr-18-24 08:00AM	Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761 (GlobeNewswire)
Apr-17-24 08:00AM	Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer (GlobeNewswire)
Mar-24-24 07:55AM	11 Best ASX Stocks To Buy Now (Insider Monkey)
Mar-05-24 08:00AM	Immutep Announces First Clinical Data from 90mg Dosing of Efti (GlobeNewswire) +11.06%
Feb-05-24 03:11AM	10 Best Australian Stocks To Buy (Insider Monkey)
Jan-30-24 08:00AM	Immutep Quarterly Activities Report Q2 FY24 (GlobeNewswire)
Jan-04-24 08:00AM	First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO in Metastatic Urothelial Cancer (GlobeNewswire)
Dec-21-23 08:00AM	Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer (GlobeNewswire)
Dec-07-23 08:00AM	Immutep Receives A$2.6 million R&D Tax Incentive from French Government (GlobeNewswire)
Nov-22-23 08:00AM	Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial (GlobeNewswire)
Nov-09-23 08:00AM	Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma (GlobeNewswire)
Nov-06-23 08:00AM	Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer (GlobeNewswire)
Nov-03-23 12:00PM	Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer (GlobeNewswire)
Nov-02-23 08:00AM	Immutep to Participate in November Investor Events (GlobeNewswire)
Oct-31-23 08:00AM	Immutep Quarterly Activities Report Q1 FY24 (GlobeNewswire)
Oct-25-23 08:00AM	Immutep receives ~A$1.13 million R&D Tax Incentive (GlobeNewswire)
Oct-24-23 08:00AM	Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023 (GlobeNewswire) -7.39%
Oct-23-23 08:00AM	Immutep's Efti in Combination with KEYTRUDA Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer (GlobeNewswire)
Oct-16-23 08:00AM	Immutep Announces Publication of Abstracts at ESMO Congress 2023 (GlobeNewswire)
Oct-03-23 08:00AM	Immutep Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting (GlobeNewswire)
Sep-21-23 08:00AM	Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use (GlobeNewswire)
Sep-05-23 09:00AM	Immutep to Participate in September Investor Conferences (GlobeNewswire)
Aug-03-23 10:03AM	Qualcomm downgraded, Wingstop upgraded: Wall Street's top analyst calls (The Fly)
Aug-01-23 08:00AM	Immutep Receives Positive Scientific Advice from European Medicines Agency (GlobeNewswire)
Jul-31-23 08:00AM	Immutep to Present Overall Survival Data in 1st Line Non-Small Cell Lung Cancer Accepted for Oral Presentation at ESMO Congress 2023 (GlobeNewswire)
08:00AM	Immutep Quarterly Activities Report Q4 FY23 (GlobeNewswire)
Jul-28-23 08:00AM	First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma (GlobeNewswire)

Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alfa (IMP321), IMP761, leramilimab (IMP701), and GSK'781 (IMP731). The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IMMP

Immutep Limited ADR

Upgrade your FINVIZ experience